Chargement en cours...
Oncogenic KRAS confers chemoresistance by upregulating NRF2
Oncogenic KRAS mutations found in 20–30% of all non-small cell lung cancers (NSCLC) are associated with chemoresistance and poor prognosis. Here we demonstrate that activation of the cell protective stress response gene NRF2 by KRAS is responsible for its ability to promote drug resistance. RNAi-med...
Enregistré dans:
| Publié dans: | Cancer Res |
|---|---|
| Auteurs principaux: | , , , , , , |
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
2014
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4268230/ https://ncbi.nlm.nih.gov/pubmed/25339352 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/0008-5472.CAN-14-1439 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|